ArticleScientific reports2026
Integrative multi-omics analysis identifies ATAD1 as a potential regulator of metastasis in pancreatic cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pancreatic cancer is one of the most invasive malignant tumors and remains a leading cause of cancer-related deaths, among which pancreatic ductal adenocarcinoma (PDAC) serves as the most common type of pancreatic cancer. Metastasis development is one of the critical reasons for the high mortality in PDAC. Previous studies usually used single or two omics integrated methods to discover biological processes and biomarkers related to the tumorigenesis and prognosis of PDAC. However, the molecular mechanisms of PDAC metastasis remain largely unknown. Therefore, we intended to integrate multi-omics data to explore the metastasis of PDAC. To identify genes or pathways that have potential roles in PDAC metastasis at different levels, we performed whole-exome sequencing (WES), RNA sequencing (RNA-Seq) and LC-MS/MS-based proteomics analysis on primary-derived (BxPC-3, MIA PaCa-2) and metastasis-derived (CFPAC-1, HPAF-II, SW1990) PDAC cell lines. Through multi-omics integrative analysis, we found that ATAD1 (ATPase Family AAA Domain Containing 1) knockdown significantly suppressed migration and invasion capacities of PDAC cells. Finally, analysis of the TCGA pancreatic adenocarcinoma (TCGA-PAAD) cohort further revealed that high ATAD1 expression was associated with significantly shorter overall survival (log-rank p = 0.012) and progressively increased from well- to poorly differentiated tumors, implicating ATAD1 as a potential regulator of metastatic propensity and dedifferentiation in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.